The Stress Urinary Incontinence drugs in development market research report provides comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Stress Urinary Incontinence. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Stress Urinary Incontinence and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Stress Urinary Incontinence by ten companies/universities/institutes. The top development phase for Stress Urinary Incontinence is phase ii with five drugs in that stage. The Stress Urinary Incontinence pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Stress Urinary Incontinence pipeline products market are: Stanford University, Cook MyoSite and Innovacell Biotechnologie.

The key targets in the Stress Urinary Incontinence pipeline products market include Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1), Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2), and Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25).

The key mechanisms of action in the Stress Urinary Incontinence pipeline product include Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Activator with one drug in IND/CTA Filed. The Stress Urinary Incontinence pipeline products include nine routes of administration with the top ROA being Intramuscular and four key molecule types in the Stress Urinary Incontinence pipeline products market including Cell Therapy, and Small Molecule.

Stress Urinary Incontinence overview

Stress urinary incontinence (SUI) is the involuntary, sudden loss of urine secondary to increased intraabdominal pressure that is affecting the patient’s quality of life. Physical activities precipitating SUI include laughing, sneezing, straining, coughing, or exercising. Patients may refer to a sudden loss of urine as “leaking”, “dripping”, or “flooding”. The patient may initially present with urinary complaints of frequency, urgency, and dysuria.

For a complete picture of Stress Urinary Incontinence’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.